ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for ACADIA Pharmaceuticals Inc. (ACAD)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
a week ago | Business Wire
a week ago | Zacks Investment Research
a week ago | Zacks Investment Research
a week ago | Business Wire
2 weeks ago | Zacks Investment Research
3 weeks ago | Business Wire
3 weeks ago | Business Wire
a month ago | Business Wire
a month ago | Newsfile Corp